Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-5346 tablets, agreeing to carry out phase III clinical trials of this product. Application indications: Reduce the risk of major adverse cardiovascular events in adult patients with confirmed atherosclerotic cardiovascular disease with elevated lipoprotein (a) or increased risk of first-time cardiovascular events.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-5346 tablets, agreeing to carry out phase III clinical trials of this product. Application indications: Reduce the risk of major adverse cardiovascular events in adult patients with confirmed atherosclerotic cardiovascular disease with elevated lipoprotein (a) or increased risk of first-time cardiovascular events.